Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline to identify potential biomarkers and to understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Arends, Rosalinda, Guo, Xiang, Baverel, Paul G., González-García, Ignacio, Xie, James, Morsli, Nassim, Yovine, Alejandro, Roskos, Lorin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993189/
https://www.ncbi.nlm.nih.gov/pubmed/33796405
http://dx.doi.org/10.1080/2162402X.2021.1898104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993189/
https://www.ncbi.nlm.nih.gov/pubmed/33796405
http://dx.doi.org/10.1080/2162402X.2021.1898104

Ejemplares similares